Vivani Medical VANI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Income Loss by Business | ||||||
| Biopharm Division | -$6.01M+3.1% | -$6.2M-5.1% | -$5.9M+7.8% | -$6.4M-13.4% | -$5.65M-2.0% | |
| Neuromodulation Division | -$768K— | —— | -$700K+12.5% | -$800K-14.3% | -$700K— | |
| Other Nonoperating Income Expense by Business | ||||||
| Biopharm Division | -$209K-112% | $1.72M+824% | -$237K+34.0% | -$359K-21.3% | -$296K-113% | |
| Neuromodulation Division | $42K— | —— | $42K+2.4% | $41K0.0% | $41K— | |
| Operating Expenses by Business | ||||||
| Biopharm Division | $6M-3.2% | $6.2M+1.6% | $6.1M-9.0% | $6.7M+11.7% | $6M— | |
| Neuromodulation Division | $800K— | —— | $600K-14.3% | $700K+16.7% | $600K— | |
| Total Assets by Business | ||||||
| Biopharm Division | $41.9M+7.7% | $38.9M+58.1% | $24.6M-12.8% | $28.2M-18.7% | $34.7M— | |
| Neuromodulation Division | $500K— | —— | $400K-42.9% | $700K0.0% | $700K— | |
| Other General And Administrative Expense by Business | ||||||
| Biopharm Division | $287K+29.3% | $222K+23.3% | $180K-18.2% | $220K+35.8% | $162K-30.5% | |
| Neuromodulation Division | $86K— | —— | $110K+2.8% | $107K+118% | $49K— | |
| Operating Lease Expense by Business | ||||||
| Biopharm Division | $1.13M+5.4% | $1.07M+6.7% | $1M-6.9% | $1.08M+1.3% | $1.06M-1.8% | |
| Neuromodulation Division | $30K— | —— | $54K-43.8% | $96K-12.7% | $110K— | |
| Labor And Related Expense by Business | ||||||
| Biopharm Division | $2.61M-3.2% | $2.7M+6.9% | $2.52M-2.6% | $2.59M+4.6% | $2.47M-0.5% | |
| Neuromodulation Division | $390K— | —— | $296K-0.7% | $298K+34.8% | $221K— | |
| Depreciation And Amortization by Business | ||||||
| Biopharm Division | $130K+16.1% | $112K+10.9% | $101K+3.1% | $98K-1.0% | $99K+7.6% | |
| Professional Services And Insurance Expense by Business | ||||||
| Biopharm Division | $1.06M+18.5% | $893K-25.6% | $1.2M-19.9% | $1.5M+13.9% | $1.32M+14.3% | |
| Neuromodulation Division | $220K— | —— | $172K-26.5% | $234K+0.9% | $232K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vivani Medical break its business down?
- Vivani Medical (VANI) reports net income loss by business across 3 parts — Biopharm Division, Neuromodulation Division and Neurostimulation Division. Each is extracted from the segment footnotes and tracked over time.
- Where does Vivani Medical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vivani Medical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.